Medical devices containing rapamycin analogs

Details Medical devices containing rapamycin analogs Medical devices containing rapamycin analogs

2002-09-10

2008-11-25

Kennedy, Sharon (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C514S291000, C514S283000

Reexamination Certificate

active

07455853

ABSTRACT:
A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to Formula (I). This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs

REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 3993749 (1976-11-01), Sehgal et al.
patent: 4316885 (1982-02-01), Rakhit
patent: 4401653 (1983-08-01), Eng
patent: 4650803 (1987-03-01), Stella et al.
patent: 4885171 (1989-12-01), Surendra et al.
patent: 4916193 (1990-04-01), Tang
patent: 4994071 (1991-02-01), MacGregor
patent: 5023262 (1991-06-01), Caufield et al.
patent: 5092877 (1992-03-01), Pinchuk
patent: 5120725 (1992-06-01), Kao et al.
patent: 5120727 (1992-06-01), Kao et al.
patent: 5120842 (1992-06-01), Failli et al.
patent: 5163952 (1992-11-01), Froix
patent: 5177203 (1993-01-01), Failli et al.
patent: 5304121 (1994-04-01), Sahatjian
patent: 5447724 (1995-09-01), Helmus
patent: 5449382 (1995-09-01), Dayton
patent: 5457111 (1995-10-01), Luly et al.
patent: 5464650 (1995-11-01), Berg et al.
patent: 5516781 (1996-05-01), Morris et al.
patent: 5527337 (1996-06-01), Stack
patent: 5527907 (1996-06-01), Or et al.
patent: 5563146 (1996-10-01), Morris et al.
patent: 5605696 (1997-02-01), Eury
patent: 5609629 (1997-03-01), Fearnot et al.
patent: 5624411 (1997-04-01), Tuch
patent: 5646160 (1997-07-01), Morris et al.
patent: 5665728 (1997-09-01), Morris et al.
patent: 5705583 (1998-01-01), Bowers
patent: 5824049 (1998-10-01), Ragheb et al.
patent: 5837313 (1998-11-01), Ding et al.
patent: 5869079 (1999-02-01), Wong et al.
patent: 6015815 (2000-01-01), Mollison
patent: 6033562 (2000-03-01), Budeit
patent: 6090901 (2000-07-01), Bowers
patent: 6096070 (2000-08-01), Ragheb et al.
patent: 6120536 (2000-09-01), Ding et al.
patent: 6273913 (2001-08-01), Wright
patent: 6284305 (2001-09-01), Ding
patent: 6358556 (2002-03-01), Ding
patent: 6413272 (2002-07-01), Igaki
patent: 6419692 (2002-07-01), Yang
patent: 6576259 (2003-06-01), Yamashita et al.
patent: 6585764 (2003-07-01), Wright et al.
patent: 2003/0129215 (2003-07-01), Millison
patent: 2003/0170287 (2003-09-01), Prescott
patent: 2005/0004661 (2005-01-01), Lewis
patent: 2006/0198867 (2006-09-01), Toner et al.
patent: 2007/0026033 (2007-02-01), Burke et al.
patent: 2007/0026034 (2007-02-01), Burket et al.
patent: 2007/0224240 (2007-09-01), Toner et al.
patent: 01184162 (1985-11-01), None
patent: 0184162 (1986-06-01), None
patent: 0467606 (1992-01-01), None
patent: 0467606 (1992-01-01), None
patent: 0747069 (2002-09-01), None
patent: 92/05179 (1992-04-01), None
patent: WO 94/21308 (1994-09-01), None
patent: 95/14023 (1995-05-01), None
patent: 98/09970 (1998-03-01), None
patent: 98/09972 (1998-03-01), None
patent: 98/36784 (1998-08-01), None
patent: 01/87372 (2001-11-01), None
patent: 02/055122 (2002-07-01), None
patent: 03/057218 (2003-07-01), None
Siekierka, et al., “A Cytosolic binding protein for the immunosuppresent FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin”. NATURE, vol. 341, Oct. 26, 1989; pp. 755-757.
Baker, et al., “Rapamycin (AY-22,989), A New Antifungal Antibiotic”. The Journal of Antibiotics, vol. XXXI, No. 6, pp. 539-545.
Vezina, et al., “Rapamycin (AY-22, 989), A New Antifungal Antibiotic, I. Taxonomy of the Producing Strepomycete and Isolation of the Active Principle”. The Journal of Antibiotics, Oct. 1975; pp. 721-726.
Sehgal, et al., “Rapamycin (AY-22, 989), A New Antifungal Antibiotic, II. Fermentation, Isolation and Characterization”. The Journal of Antibiotics vol. XXVIII, No. 10, pp. 727-732.
Poste, et al., “Lipid Vesicles as Carriers For Introducing Biologically Active Materials Into Cells”.
Randall Ellis Morris, “Rapamycins: Antifungal, Antitumor, Antiproliferative, and Immunosuppressive Macrolides”. Transplantation Reviews, vol. 6, No. 1, Jan. 1992; pp. 39-87.
Bunchman, et al., “Smooth Muscle Cell Proliferation by Conditioned Media From Cyclosporine-Treated Endothelial Cells: A Role of Endothelin”. Transplantation Proceedings, vol. 23, No. 1, Feb. 1991; pp. 967-968.
Kino, et al., “Effect of FK-506 on Human Mixed Lymphocyte Reaction In Vitro”. Transplatation Proceedings, vol. XIX, No. 5, Suppl 6, Oct. 1987; pp. 36-39.
Yamagishi, et al., “Endothelin 1 Mediates Endothelial Cell-Dependent Proliferation of Vascular Pericytes”. Biochemical and Biophysical Research Communications, vol. 191, No. 3, Mar. 1993; 840-846.
Martel, et al., “Inhibition of the immune response by rapamycin, a new antifungal antibiotic”. Can. J. Physiol. Pharmacol. vol. 55, 1997.
Sabatini et al., “RAFT1: A Mammalian Protein That Binds to FKBP12 in a Rapamycin-Dependent Fashion and Is Homologous to Yeast TORs”. Cell, vol. 78, Jul. 15, 1994; pp. 35-43.
Sehgal, et al., “Demethoxyrapamycin (AY-24, 668), A New Antifungal Antibiotic”. The Journal of Antibiotics, vol. XXXVI, No. 4, pp. 351-354.
Bierer, et al., “The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation”. Eur. J. Immunol., vol. 21, 1991; pp. 439-445.
Shichiri, et al., “Endothelin—1 is an Autocrine/Paracrine Growth Factor for Human Cancer Cell Lines”. J. Clin. Invest. The American Society for Clinical Investigation, Inc. vol. 87, May 1991; pp. 1867-1871.
Dumont et al., “The Immunosuppressive Macrolides FK-506 and Rapamycin A6T AS Reciprocal Antagonists In Murine T Cells”. The Journal of Immunology, vol. 144, Feb. 15, 1990; pp. 1418-1424.
Fretz et al., “Rapamycin and FK506 Binding Proteins (Immunophilins)”. Journal American Chemical Society, vol. 113, 1991; pp. 1409-1411.
Romo et al., “Total Synthesis of (-)-Rapamycin Using an Evans—Tishchenko Fragment Coupling”. Journal American Chemical Society, vol. 115, 1993; pp. 7906-7907.
Hayward et al., “total Synthesis of Rapamycin via a Novel Titanium—Mediated Aldol Macrocyclization Reaction”. Journal American Chemical Society, vol. 115, 1993; pp. 9345-9346.
Brown et al., “A mammalian protein targeted by G1-arresting rapamycin receptor complex”. NATURE, vol. 369, Jun. 30, 19994; pp. 756-758.
Paiva et al., “Incorporation into Rapamycin”. Journal of Natural Products, vol. 54, No. 1, Jan.-Feb. 1991; pp. 169-177.
Harding et al., “A receptor for the immunosuppressant FK506 is acis-transpeptidyl-prolyl isomerase”. NATURE, vol. 341, Oct. 26, 1989; pp. 758-760.
Suzuki, et al., Stent—Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model, Circulation, pp. 1188-1193 (2001).
Aggarwal, A., D.J. Schneider, B.E. Sobel, and H.L. Dauerman. 2003. Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. Am J Cardiol. 92:924-9.
Baker, H., A. Sidorowicz, S.N. Sehgal, and C. Vezina. 1978. Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (Tokyo). 31:539-45.
Bierer, B.E., S.L. Schreiber, and S.J. Burakoff. 19

Affiliated with

Also associated with

Rating

Medical devices containing rapamycin analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medical devices containing rapamycin analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical devices containing rapamycin analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4021321